LifeSpeak (TSE:LSPK – Get Rating) had its price objective lowered by equities researchers at TD Securities from C$0.90 to C$0.65 in a research report issued to clients and investors on Wednesday, BayStreet.CA reports. The brokerage presently has a “hold” rating on the stock.
Several other research firms have also recently issued reports on LSPK. Royal Bank of Canada lowered their target price on shares of LifeSpeak from C$0.80 to C$0.60 and set a “sector perform” rating on the stock in a research note on Tuesday. Cormark decreased their price target on shares of LifeSpeak from C$1.75 to C$0.90 in a report on Tuesday, April 4th. Canaccord Genuity Group dropped their price objective on shares of LifeSpeak from C$1.50 to C$1.00 in a report on Tuesday. Finally, Stifel Nicolaus dropped their price target on LifeSpeak from C$2.50 to C$1.10 in a research note on Thursday, April 27th.
LifeSpeak Price Performance
The company has a market capitalization of C$22.91 million and a price-to-earnings ratio of -0.49. LifeSpeak has a twelve month low of C$0.35 and a twelve month high of C$2.71. The company has a quick ratio of 0.40, a current ratio of 0.40 and a debt-to-equity ratio of 241.08. The stock has a 50 day moving average of C$0.51 and a two-hundred day moving average of C$0.99.
About LifeSpeak
LifeSpeak Inc provides software-as-a-service solutions for digital mental, physical and total wellbeing resources for mid and enterprise-sized organizations in Canada and internationally. The company offers digital educational resources, such as easily consumable videos, podcasts, and tailored articles for depression, stress management, and financial health; and on-demand workout library, automated, and live sessions in areas, including general fitness, mindfulness, cardio, strength, yoga, pre-natal, Pilates, and others.
Featured Articles
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for LifeSpeak Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeSpeak and related companies with MarketBeat.com's FREE daily email newsletter.
